Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hypoxic cell macromolecules, as a target class, refer to cellular proteins, nucleic acids, and other large biomolecules within cells that are located in regions of low oxygen (hypoxia), particularly within solid tumors. These macromolecules become the site of covalent binding or "trapping" by certain bioreductive drugs or probes that are selectively activated under hypoxic conditions. Bioreductive trapping involves prodrugs or imaging agents that are enzymatically reduced in low oxygen environments, forming reactive species capable of covalently binding to intracellular macromolecules such as proteins and DNA, leading to selective accumulation of the agent in hypoxic regions.
Covalent binding to intracellular macromolecules following enzymatic reduction under hypoxic conditions. This leads to accumulation of the drug or probe specifically in oxygen-deprived regions.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypoxic Cell Macromolecules (via Bioreductive Trapping).